Ambu A/S (AMBUb)

102.2
-0.9(-0.87%)
  • Volume:
    889,688
  • Bid/Ask:
    0.0/0.0
  • Day's Range:
    100.6 - 103.8
Earnings results expected today

Ambu will announce its quarterly financial results today. Traders should take this into account as the share price often fluctuates around this time period.

AMBUb Overview

Prev. Close
103.1
Day's Range
100.6-103.8
Revenue
4.44B
Open
101.2
52 wk Range
61.3-131.1
EPS
0.366
Volume
889,688
Market Cap
25.86B
Dividend (Yield)
0.29
(0.31%)
Average Vol. (3m)
1,021,041
P/E Ratio
280.05
Beta
0.631
1-Year Change
-24.88%
Shares Outstanding
254,074,119
Next Earnings Date
Feb 07, 2023
What is your sentiment on Ambu?
or
Market is currently closed. Voting is open during market hours.

Ambu A/S News

Ambu A/S Company Profile

Ambu A/S Company Profile

Employees
5000
Market
Denmark
  • Type:Equity
  • Market:Denmark
  • ISIN:DK0060946788
  • S/N:223396432

Ambu A/S is a Denmark-based company engaged in the development, manufacture and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products such as resuscitators, face masks and laryngeal masks. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The Company markets its products worldwide. The Company operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.

Read More

Analyst Price Target

Average101.2 (-1.0% Downside)
High140.0
Low72.0
Price102.2
No. of Analysts5
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellBuyStrong BuyNeutral
Technical IndicatorsStrong SellSellSellBuyStrong Sell
SummaryStrong SellSellNeutralStrong BuySell
  • Ambu (AMBU B) initiated with a Buy at Berenberg, Berenberg analyst Michael Healy initiated coverage of Ambu with a Buy rating and DKK 291 price target. Ambu is a leader in the "nascent" single-use endoscopy market, one of the fastest-growing segments in medical technology.
    1
    • Sack them all. Big talking American with their grand ideas of Sales at all cost.. . . Down here in Australia, every single American CEO they have tried in the past 20 years have run their companies to the ground and smashed the culture.. . . A great shame I have a very large position in this otherwise great company
      1
      • Feels like the Board of Directors do not like us shareholders. Time to spill the Board. Literally billions in value has been destroyed.
        0
        • They should not have cut Lars.
          0
        • René Rasmussen  Yep, gargantuan mistake. If you read the story of the Chairman, you will see he was fired as CEO from ALK in 2016. Was this revenge because he feels he was treated poorly? Either way I will post on their Facebook soon as I did here. It has cost me a lot of money.
          0
      • Remember when Lundbeck lost their CEO two years ago.. Same reaction and then soon forgotten.
        1
        • Ucchhh what fall today, and I just buy up in the fall. Hope it Will repair next week.
          0
          • Ambu is still a strong case. But it will take some month to stabelice.
            0
          • The leadership of ambu handles it without care.
            0